276 related articles for article (PubMed ID: 23326351)
21. Plasticity and Epitope Exposure of the HIV-1 Envelope Trimer.
Powell RLR; Totrov M; Itri V; Liu X; Fox A; Zolla-Pazner S
J Virol; 2017 Sep; 91(17):. PubMed ID: 28615206
[TBL] [Abstract][Full Text] [Related]
22. Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation.
Kumar R; Tuen M; Li H; Tse DB; Hioe CE
Vaccine; 2011 Nov; 29(48):9064-74. PubMed ID: 21945958
[TBL] [Abstract][Full Text] [Related]
23. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
[TBL] [Abstract][Full Text] [Related]
24. Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140.
Stamatos NM; Mascola JR; Kalyanaraman VS; Louder MK; Frampton LM; Birx DL; VanCott TC
J Virol; 1998 Dec; 72(12):9656-67. PubMed ID: 9811699
[TBL] [Abstract][Full Text] [Related]
25. Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120.
Pan R; Qin Y; Banasik M; Lees W; Shepherd AJ; Cho MW; Kong XP
J Virol; 2018 Apr; 92(7):. PubMed ID: 29343576
[TBL] [Abstract][Full Text] [Related]
26. Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.
Townsley S; Li Y; Kozyrev Y; Cleveland B; Hu SL
J Virol; 2016 Jan; 90(2):829-41. PubMed ID: 26512079
[TBL] [Abstract][Full Text] [Related]
27. Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope.
Zolla-Pazner S; Cohen S; Pinter A; Krachmarov C; Wrin T; Wang S; Lu S
Virology; 2009 Sep; 392(1):82-93. PubMed ID: 19632700
[TBL] [Abstract][Full Text] [Related]
28. Design of a non-glycosylated outer domain-derived HIV-1 gp120 immunogen that binds to CD4 and induces neutralizing antibodies.
Bhattacharyya S; Rajan RE; Swarupa Y; Rathore U; Verma A; Udaykumar R; Varadarajan R
J Biol Chem; 2010 Aug; 285(35):27100-27110. PubMed ID: 20558728
[TBL] [Abstract][Full Text] [Related]
29. Molecular Basis of Unusually High Neutralization Resistance in Tier 3 HIV-1 Strain 253-11.
Moyo T; Ereño-Orbea J; Jacob RA; Pavillet CE; Kariuki SM; Tangie EN; Julien JP; Dorfman JR
J Virol; 2018 Jul; 92(14):. PubMed ID: 29618644
[TBL] [Abstract][Full Text] [Related]
30. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
[TBL] [Abstract][Full Text] [Related]
31. Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence.
Honnen WJ; Krachmarov C; Kayman SC; Gorny MK; Zolla-Pazner S; Pinter A
J Virol; 2007 Feb; 81(3):1424-32. PubMed ID: 17121806
[TBL] [Abstract][Full Text] [Related]
32. Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFL.
Kumar R; Pan R; Upadhyay C; Mayr L; Cohen S; Wang XH; Balasubramanian P; Nádas A; Seaman MS; Zolla-Pazner S; Gorny MK; Kong XP; Hioe CE
J Virol; 2015 Sep; 89(17):9090-102. PubMed ID: 26109728
[TBL] [Abstract][Full Text] [Related]
33. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting.
Richmond JF; Mustafa F; Lu S; Santoro JC; Weng J; O'Connell M; Fenyö EM; Hurwitz JL; Montefiori DC; Robinson HL
Virology; 1997 Apr; 230(2):265-74. PubMed ID: 9143282
[TBL] [Abstract][Full Text] [Related]
34. Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1.
Wang S; Arthos J; Lawrence JM; Van Ryk D; Mboudjeka I; Shen S; Chou TH; Montefiori DC; Lu S
J Virol; 2005 Jun; 79(12):7933-7. PubMed ID: 15919951
[TBL] [Abstract][Full Text] [Related]
35. Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies.
Shen G; Upadhyay C; Zhang J; Pan R; Zolla-Pazner S; Kong XP; Hioe CE
PLoS One; 2015; 10(10):e0141233. PubMed ID: 26491873
[TBL] [Abstract][Full Text] [Related]
36. Levels of N-linked glycosylation on the V1 loop of HIV-1 Env proteins and their relationship to the antigenicity of Env from primary viral isolates.
Huang Z; Chou A; Tanguay J; Shen S; Mboudjeka I; Chou TH; Lu S; Wang S
Curr HIV Res; 2008 Jun; 6(4):296-305. PubMed ID: 18691028
[TBL] [Abstract][Full Text] [Related]
37. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9.
McLellan JS; Pancera M; Carrico C; Gorman J; Julien JP; Khayat R; Louder R; Pejchal R; Sastry M; Dai K; O'Dell S; Patel N; Shahzad-ul-Hussan S; Yang Y; Zhang B; Zhou T; Zhu J; Boyington JC; Chuang GY; Diwanji D; Georgiev I; Kwon YD; Lee D; Louder MK; Moquin S; Schmidt SD; Yang ZY; Bonsignori M; Crump JA; Kapiga SH; Sam NE; Haynes BF; Burton DR; Koff WC; Walker LM; Phogat S; Wyatt R; Orwenyo J; Wang LX; Arthos J; Bewley CA; Mascola JR; Nabel GJ; Schief WR; Ward AB; Wilson IA; Kwong PD
Nature; 2011 Nov; 480(7377):336-43. PubMed ID: 22113616
[TBL] [Abstract][Full Text] [Related]
38. Comparing antigenicity and immunogenicity of engineered gp120.
Selvarajah S; Puffer B; Pantophlet R; Law M; Doms RW; Burton DR
J Virol; 2005 Oct; 79(19):12148-63. PubMed ID: 16160142
[TBL] [Abstract][Full Text] [Related]
39. Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120.
Pinter A; Honnen WJ; Kayman SC; Trochev O; Wu Z
Vaccine; 1998 Nov; 16(19):1803-11. PubMed ID: 9795384
[TBL] [Abstract][Full Text] [Related]
40. Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.
Krachmarov C; Pinter A; Honnen WJ; Gorny MK; Nyambi PN; Zolla-Pazner S; Kayman SC
J Virol; 2005 Jan; 79(2):780-90. PubMed ID: 15613306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]